Tribunal was “wrong” to reject CMA phenytoin decision, says Court

The case revolves around the Competition and Markets Authority's (CMA) decision regarding phenytoin, a medication used to treat epilepsy. Phenytoin is a generic drug, and the CMA's decision likely relates to its pricing or distribution in the UK market. The Court's ruling on the tribunal's decision may have implications for the pharmaceutical industry and the regulation of generic medicines.

Tribunal was “wrong” to reject CMA phenytoin decision, says Court